AU2019246983B2 - Erenumab compositions and uses thereof - Google Patents

Erenumab compositions and uses thereof

Info

Publication number
AU2019246983B2
AU2019246983B2 AU2019246983A AU2019246983A AU2019246983B2 AU 2019246983 B2 AU2019246983 B2 AU 2019246983B2 AU 2019246983 A AU2019246983 A AU 2019246983A AU 2019246983 A AU2019246983 A AU 2019246983A AU 2019246983 B2 AU2019246983 B2 AU 2019246983B2
Authority
AU
Australia
Prior art keywords
erenumab
composition
variants
amount
isomerization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019246983A
Other languages
English (en)
Other versions
AU2019246983A1 (en
Inventor
Suminda Hapuarachchi
Kenneth Lawson
Jose Gregorio Ramirez
Noel Rieder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU2019246983A1 publication Critical patent/AU2019246983A1/en
Application granted granted Critical
Publication of AU2019246983B2 publication Critical patent/AU2019246983B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2019246983A 2018-04-02 2019-04-01 Erenumab compositions and uses thereof Active AU2019246983B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02
US62/651,651 2018-04-02
PCT/US2019/025223 WO2019195185A1 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Publications (2)

Publication Number Publication Date
AU2019246983A1 AU2019246983A1 (en) 2020-10-29
AU2019246983B2 true AU2019246983B2 (en) 2025-12-18

Family

ID=66248665

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019246983A Active AU2019246983B2 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Country Status (19)

Country Link
US (2) US11407838B2 (enExample)
EP (1) EP3774881A1 (enExample)
JP (3) JP7840636B2 (enExample)
KR (1) KR20200139720A (enExample)
CN (1) CN111954678A (enExample)
AR (1) AR114722A1 (enExample)
AU (1) AU2019246983B2 (enExample)
BR (1) BR112020019882A2 (enExample)
CA (1) CA3095899A1 (enExample)
CL (2) CL2020002519A1 (enExample)
EA (1) EA202092335A1 (enExample)
IL (1) IL277663A (enExample)
MA (1) MA52202A (enExample)
MX (1) MX2020010320A (enExample)
PH (1) PH12020551618A1 (enExample)
SA (1) SA520420261B1 (enExample)
SG (1) SG11202009629YA (enExample)
TW (1) TWI847980B (enExample)
WO (1) WO2019195185A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2022232376A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
EP4455163A4 (en) * 2021-12-22 2025-12-24 Chugai Pharmaceutical Co Ltd REDUCED BIOLOGICALLY ACTIVE ANTIBODY VARIANT
CN115819589A (zh) * 2022-10-19 2023-03-21 武汉人福创新药物研发中心有限公司 一种培养基及生产抗cgrpr抗体的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207763A1 (en) * 2013-06-25 2014-12-31 Cadila Healthcare Limited Purification process for monoclonal antibodies

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1084136B1 (en) 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
SI1556020T1 (sl) 2002-08-12 2009-08-31 Birkir Sveinsson Uporaba spojin, ki so antagonisti CGRP, za zdravljenje psoriaze
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
AU2005310305A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
KR20090039739A (ko) 2006-08-03 2009-04-22 아스트라제네카 아베 αＶβ６에 대해 작용하는 항체 및 그의 용도
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
US20120027772A1 (en) * 2008-11-20 2012-02-02 Genentech, Inc. Therapeutic protein formulations
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
CN102471377B (zh) * 2009-07-24 2015-04-22 霍夫曼-拉罗奇有限公司 优化抗体的生产
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
DK3272764T3 (da) 2009-12-18 2024-05-06 Novartis Ag Fremgangsmåde til affinitetskromatografi
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
JP6292718B2 (ja) 2011-07-01 2018-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝集ポリペプチドから単量体ポリペプチドを分離するための方法
AU2012347545A1 (en) 2011-12-07 2014-06-12 Amgen Inc. IgG2 disulfide isoform separation
BR112014011900A2 (pt) 2011-12-15 2017-05-16 Hanwha Chemical Corp um método de purificação de anticorpo
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
EP3019516B1 (en) * 2013-07-12 2018-11-14 H. Hoffnabb-La Roche Ag Elucidation of ion exchange chromatography input optimization
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2017003247A (es) * 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
TWI728953B (zh) * 2015-04-24 2021-06-01 美商安美基公司 治療或預防偏頭痛之方法
AR104847A1 (es) 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014207763A1 (en) * 2013-06-25 2014-12-31 Cadila Healthcare Limited Purification process for monoclonal antibodies

Also Published As

Publication number Publication date
EP3774881A1 (en) 2021-02-17
US11407838B2 (en) 2022-08-09
BR112020019882A2 (pt) 2021-01-05
TW202003572A (zh) 2020-01-16
TWI847980B (zh) 2024-07-11
WO2019195185A1 (en) 2019-10-10
PH12020551618A1 (en) 2021-08-16
US20220348673A1 (en) 2022-11-03
AR114722A1 (es) 2020-10-07
US20190300617A1 (en) 2019-10-03
SA520420261B1 (ar) 2024-05-23
MA52202A (fr) 2021-02-17
JP2023103323A (ja) 2023-07-26
JP2026034591A (ja) 2026-02-27
CA3095899A1 (en) 2019-10-10
KR20200139720A (ko) 2020-12-14
AU2019246983A1 (en) 2020-10-29
CL2023000491A1 (es) 2023-10-13
JP2021519790A (ja) 2021-08-12
SG11202009629YA (en) 2020-10-29
JP7840636B2 (ja) 2026-04-06
MX2020010320A (es) 2021-01-08
EA202092335A1 (ru) 2021-01-22
CN111954678A (zh) 2020-11-17
IL277663A (en) 2020-11-30
CL2020002519A1 (es) 2021-04-05

Similar Documents

Publication Publication Date Title
US20220348673A1 (en) Erenumab compositions and uses thereof
JP7191076B2 (ja) Ｆｇｆ２１突然変異体及びその使用
Jacobsen et al. Engineering an IgG scaffold lacking effector function with optimized developability
TWI436776B (zh) Ｆｇｆ２１突變體及其用途
Gao et al. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation
US9649383B2 (en) Liquid formulations for TNFR:Fc fusion proteins
US20150329628A1 (en) Liquid formulations for an anti-tnf alpha antibody
RS59179B1 (sr) Formulacije etanercepta stabilizovane jonima magnezijuma
JP2026509221A (ja) ヘテロ二量体リラキシン融合タンパク質を含む医薬製剤及びその使用
EA044658B1 (ru) Композиции на основе эренумаба и пути их применения
AU2019251452A2 (en) Stable antibody formulation
HK40040918A (en) Erenumab compositions and uses thereof
WO2025096932A1 (en) Methods for reducing lipase activity using stress

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)